FCHSD2 Activators
FCHSD2 Activators are a diverse group of chemical compounds that enhance the functional activity of FCHSD2 through a variety of signaling mechanisms. Forskolin, for instance, indirectly augments FCHSD2 activity by increasing cellular levels of cAMP, which in turn activates PKA. PKA then phosphorylates various target proteins, potentially including those associated with FCHSD2, leading to enhanced organization of the cytoskeleton and signaling functions where FCHSD2 is involved. Phorbol 12-myristate 13-acetate (PMA) is another activator that works by stimulating protein kinase C (PKC), which may phosphorylate proteins in close connection with FCHSD2, thereby influencing its role in actin-cytoskeletal reorganization. Compounds like Calyculin A and Okadaic Acid act as phosphatase inhibitors, preventing the dephosphorylation of proteins that interact with FCHSD2, resulting in a sustained activation state of FCHSD2-mediated pathways.
The modulation of FCHSD2 activity continues with compounds that directly affect the actin cytoskeleton, a structure closely regulated by FCHSD2. Epigallocatechin Gallate (EGCG), through its ability to influence various kinases, could potentiate the signaling pathways that govern cytoskeletal rearrangement, thereby enhancing the activity of FCHSD2. Jasplakinolide, by stabilizing actin filaments, supports actin polymerization, which in turn could increase the activity of FCHSD2 in organizing the cytoskeleton. In contrast, Cytochalasin D disrupts actin polymerization, which could paradoxically lead to enhanced activity of FCHSD2 as the cell attempts to maintain cytoskeletal organization. Blebbistatin, an inhibitor of myosin II ATPase activity, and ML-7, which inhibits myosin light chain kinase (MLCK), both change actin-myosin interaction dynamics, potentially requiring a compensatory increase in FCHSD2 activity. Wiskostatin, as an inhibitor of the N-WASP, indirectly could enhance FCHSD2-associated pathways by leading to increased activity of FCHSD2 in actin cytoskeletal reorganization.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly activates adenylyl cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA, which can phosphorylate various proteins, potentially including those associated with FCHSD2, leading to enhanced cytoskeletal organization and signaling function of FCHSD2. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which may phosphorylate substrates associated with FCHSD2, influencing its role in actin-cytoskeletal reorganization and potentially enhancing its activity in cellular signaling pathways. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A is a potent inhibitor of protein phosphatases 1 and 2A. Inhibition of these phosphatases can result in increased phosphorylation of proteins within pathways involving FCHSD2, leading to an enhancement of its activity related to cytoskeletal dynamics. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Similar to Calyculin A, Okadaic Acid inhibits protein phosphatases PP1 and PP2A, potentially increasing the phosphorylation state of proteins that interact with or regulate FCHSD2, thus enhancing its functional activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG can modulate various kinases and has been shown to have a role in cytoskeletal organization. It may enhance FCHSD2 activity by influencing signaling pathways that govern cytoskeletal rearrangement, where FCHSD2 is potentially involved. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments and could enhance FCHSD2 activity by promoting actin polymerization, which may be beneficial for its cytoskeletal organizing functions. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D disrupts actin polymerization. By inhibiting normal actin dynamics, it may create a cellular context that requires enhanced activity of FCHSD2 to maintain cytoskeletal organization. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Blebbistatin is an inhibitor of myosin II ATPase activity. By affecting myosin II function, it can alter the actin-myosin interaction and potentially enhance the activity of FCHSD2 in actin cytoskeletal reorganization. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK). Inhibition of MLCK could lead to changes in actin dynamics, potentially necessitating an increased activity of FCHSD2 in its role in cytoskeletal organization. | ||||||
FLI-06 | 313967-18-9 | sc-497529 | 5 mg | $82.00 | ||
Wiskostatin is an inhibitor of the N-WASP, a regulator of actin polymerization. By inhibiting N-WASP, wiskostatin could indirectly enhance FCHSD2 associated pathways involved in actin cytoskeletal reorganization, potentially leading to increased activity of FCHSD2. | ||||||